

## For Patients with Operable Melanoma

### EA6194 Available Through ECOG-ACRIN Cancer Research Group

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

#### Patient Population

See Section 3.0 for Complete Eligibility Details

- Age ≥18 years, ECOG PS 0-1, and adequate lab values
- Must have a histologic diagnosis of melanoma belonging to T0, Tx, or T1-4; and N1b, N2b, N2c, N3b or N3c (AJCC 8th ed.)
- May have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; OR may have a history of primary melanoma/unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to the groups listed per protocol
- Must be a candidate for definitive surgery and meet with the treating surgical oncologist prior to randomization
- Must not have received any live vaccine within 30 days of randomization and during study (see protocol for details)
- Must have the presence of injectable (defined per protocol) and measurable disease (RECIST 1.1), documented by scans within 4 weeks of randomization
- No prior systemic therapy for melanoma including systemic therapy with an anti-PD-1/PD-L1/CTLA-4, BRAF/MEK inhibitor combination and/or TLR-9 agonist
- Must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy/any other form of immunosuppressive therapy within 7 days of randomization (exceptions per protocol)
  - ◊ Patients with adrenal insufficiency are ineligible
- No active infection requiring systemic therapy
- No history of brain metastases
- Patients should be NYHA class 2B or better, if indicated
- Must not have had an allogeneic tissue/solid organ transplant
- No history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Must not have ≥ Grade 3 hypersensitivity to pembrolizumab and/or any of its excipients

#### Treatment Plan

See Section 5.0 for Complete Treatment Details

##### Neoadjuvant Phase:

- 1 cycle = 21 days (visit window +/- 2 days); 3 cycles for 9 weeks
- **Arm A:** Pembrolizumab 200 mg IV day 1, for a total of 3 cycles/doses
- **Arm B:**
  - ◊ CMP-001 5mg subQ day 1 cycle 1, then 10 mg intratumorally thereafter on CID8, CID15, C2D1, C2D8, C2D15, C3D1 (total of 6 doses)
  - ◊ Pembrolizumab 200 mg IV day 8 of each cycle for a total of 3 cycles/doses

##### Surgery:

- To be performed approximately 1-2 weeks after completion of neoadjuvant phase in the absence of limiting toxicities
- Surgical guidelines are general and may be followed/modified at the discretion of the expert surgical oncologist

##### Adjuvant Phase:

- 16 cycles for 48 weeks
- **Both arms:** Pembrolizumab 400 mg IV day 1 every other cycle (every 6 weeks) for up to 8 doses

##### Notes:

- *Vital signs to be collected per protocol*
- *Prophylaxis before CMP-001 is required. Patients must be observed for at least 4 hours following each of the first 6 CMP-001 injections; the observation period may be reduced starting with the 7th injection*
- *When CMP-001 and pembrolizumab fall on the same visit, CMP-001 must precede pembrolizumab*

#### Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN) <https://open.ctsu.org/open>

#### Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, <http://ecog-acrin.org> (Member Login)


## Please Enroll Your Eligible Patients!

**Study Chair:**  
Ahmad Tarhini, MD, PhD

**Study Co-Chair:**  
Diwakar Davar, MD

# EA6194

## Schema



1. Neoadjuvant and Adjuvant cycle length: 1 cycle = 21 days
2. After treatment is complete, patients will be followed for response until progression and for survival for a total of 15 years from the date of randomization